Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a verbal warning into a lawsuit. In a lawsuit filed Thursday in a New ...

Caroline Litchfield; Chief Financial Officer, Executive Vice President; Merck & Co Inc Dean Li; Executive Vice President, President - Merck Research Laboratories; Merck & Co Inc Thank you for ...

Merck expects $200 million in added tariff costs, primarily impacting gross margins. The company has invested $12 billion since 2017, with another $9 billion planned to expand U.S. manufacturing ...

Merck KGaA is edging closer to the SpringWorks deal, which was first rumoured in February, confirming late-stage negotiations at an estimated price of $47 per share – potentially valuing the ...

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid an escalating trade war between the US and China, where demand for its blockbuster Gardasil vaccine is ...

Halozyme Therapeutics (NASDAQ:HALO) on Thursday announced a lawsuit against Merck (NYSE:MRK) over allegations that an injectable version of the New Jersey-based pharma giant’s blockbuster cancer ...

A biotech company is suing Merck & Co. over its easier-to-use version of its blockbuster cancer treatment Keytruda, alleging the pharmaceutical giant violated its intellectual property.

Merck & Co. cut its 2025 earnings outlook, partly to account for recently imposed tariffs that it projects will total $200 million. The projection comes in light of the tariffs implemented so ...

Halozyme Therapeutics is suing Merck for patent infringement. The San Diego biotechnology company said Thursday it believes a proposed form of Merck's cancer medicine Keytruda uses a formulation ...

Merck said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the U.S. and China. The estimate doesn’t account for the possibility that ...

Merck, while steadfast in its manufacturing push that aligns with the administration’s focus, is no different as it prepares for challenges ahead. While the company reaffirmed its full-year ...

Reacting to press speculation, Merck KGaA has acknowledged that talks to buy US biotech SpringWorks are now in the late stages and are revolving around an offer of around $47 per share.